# A Study of Ad26.COV2.S in Adults (COVID-19)

> **NCT04509947** · PHASE1 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 250 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Ad26.COV2.S
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04509947
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-11
- **Primary completion:** 2021-02-22
- **Final completion:** 2021-11-16
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2021-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04509947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04509947, "A Study of Ad26.COV2.S in Adults (COVID-19)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04509947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*